Assembly Bill 1776, legislation intended to strengthen antitrust enforcement, could unintentionally disrupt the collaborations that make clinical trials possible.

Many researchers prefer the “live” data that comes from real-world results while still acknowledging potential shortcomings.

Scientists often encounter translational barriers when moving drug candidates from the laboratory to the clinic.

An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator ...

Clinical trial participation is associated with improved survival for patients with some genitourinary cancers, but racial, ethnic, age, gender, and socioeconomic disparities appe ...

New peer-reviewed study highlights safety and clinical benefits of intradiscal MSC therapy for chronic low back pain ...

Expanding local access to clinical trials improves options by reducing barriers and bringing research opportunities closer to ...

Learn why representation in atopic dermatitis clinical trials matters for people of color, as well as the benefits, risks, ...

Stem cell transplantation could be a rapid and effective way to restore hemoglobin production in individuals with the blood ...

The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN trial, testing the effectiveness of an investigational drug in patients with prosthetic joint infections following ...

The Dementia Trials Accelerator has taken a significant step towards transforming dementia clinical trials in the UK by welcoming its first participants into clinics for simple tests that ...

The integration of Artificial Intelligence (AI) with multimodal medical data is an emerging field in biomedical informatics, aiming to enhance the accuracy ...